Toxicological Profiling and Safety Assessment of NASAT 2.0: A Conceptual Framework for Adaptive Nanoparticle Therapy in Rabies

Year : 2026 | Volume : 16 | Issue : 02 | Page : 1 19
By

Mahammad Zaid Md Atik,

Yash Nitin Pawar,

  1. Student (Pharmacy), Department of Pharmacy, Jagadambha Institute of Pharmacy and Research, Kalamb, Maharashtra, India
  2. Pharmacist, Department of Pharmacy, Yashodeep Institute of Pharmacy and Research, Pimpalgaon, Pandhari, Maharashtra, India

Abstract

Rabies, caused by the highly neurotropic Rabies lyssavirus, remains one of the most enigmatic and universally lethal infectious diseases known to modern medicine. Once clinical symptoms manifest following successful neuroinvasion, the fatality rate approaches absolute certainty (approximately 99.9%), a staggering statistic that has remained largely unchallenged despite massive, concurrent advances in modern virology, critical care medicine, and cellular immunology. Current late-stage therapeutic protocols, most notably the widely debated Milwaukee Protocol, have systematically failed to provide reproducible survival outcomes. This widespread failure is primarily due to two factors: the strict anatomical impermeability of the blood–brain barrier (BBB) to systemic therapeutic agents, and the virus’s highly sophisticated, multilayered intracellular immune evasion mechanisms. This comprehensive report presents a hypothesized therapeutic intervention, exhaustive analytical framework for NASAT 2.0 (Neuro-Adaptive Synergistic Advanced Therapy), a novel conceptual therapeutic architecture designed specifically to eradicate symptomatic rabies. NASAT 2.0 utilizes an infection-responsive, adaptive polymeric nanoparticle platform to deliver a precisely sequenced payload of pharmacological agents directly into the central nervous system (CNS). The protocol incorporates: Memantine for critical glutamate-mediated neuroprotection, Minocycline for localized anti-apoptotic and anti-inflammatory action, Favipiravir for highly potent RNA-dependent RNA polymerase (RdRp) viral suppression via lethal mutagenesis, and a combination of targeted Interferon-beta and Monoclonal Antibodies for final host-mediated immune clearance. By leveraging the SynB1 cell-penetrating peptide and RVG29 neurotropic targeting ligands for effective BBB adsorptive and receptor-mediated transcytosis and utilizing highly specific stimuli-responsive polymers (pH-labile and ROS-sensitive linkers) for localized, controlled intracellular release, NASAT 2.0 systematically resolves the pharmacokinetic failures of all legacy therapies. This extensive report synthesizes molecular pharmacology, cutting-edge biomedical nanotechnology, advanced pharmacokinetic mathematical modeling, manufacturing protocols, and clinical immunology to demonstrate how this precise, multi-modal approach can theoretically achieve unprecedented survival rates without the devastating, dose-limiting systemic toxicity observed in previous medical regimens. Toxicology Objective: The objective of this paper is to provide a toxicity-focused conceptual framework. It evaluates the theoretical safety profile, risk factors, and nanotoxicological limits of deploying the proposed NASAT 2.0 carrier within the central nervous system.

Keywords: Toxicology, Rabies lyssavirus, Polymeric Nanoparticles, Blood–Brain Barrier (BBB), Neuroprotection, Favipiravir, receptor-mediated transcytosis, pharmacokinetic modeling, neuroadaptive therapy, GMP manufacturing

[This article belongs to Research and Reviews: A Journal of Toxicology ]

How to cite this article: Mahammad Zaid Md Atik, Yash Nitin Pawar. Toxicological Profiling and Safety Assessment of NASAT 2.0: A Conceptual Framework for Adaptive Nanoparticle Therapy in Rabies. Research and Reviews: A Journal of Toxicology. 2026; 16(02):1-19.
How to cite this URL: Mahammad Zaid Md Atik, Yash Nitin Pawar. Toxicological Profiling and Safety Assessment of NASAT 2.0: A Conceptual Framework for Adaptive Nanoparticle Therapy in Rabies. Research and Reviews: A Journal of Toxicology. 2026; 16(02):1-19. Available from: https://journals.stmjournals.com/rrjot/article=2026/view=251712

References

  1. Kim J, Lee S, Park H, Choi Y, Kang M, Lee J, et al. Rabies virus-targeting NIR-II phototheranostics for precise diagnosis and treatment of rabies infection. ACS Nano. 2025;19(5):10234–10249. doi: 1021/acsnano.5c01234.
  2. Hooper DC, Roy A, Kean RB, Phares TW, Barkhouse DA. Therapeutic immune clearance of rabies virus from the central nervous system. Proc Natl Acad Sci U S A. 2011;108(3):1300–1305. doi: 1073/pnas.1012065108.
  3. Li Z, Zhao L, Wang X, Zhou Y, Chen S, Wang Y. Memantine relieves neuronal impairment caused by neurotropic virus infection through NMDA receptor modulation. Antiviral Res. 2019;161:1–10. doi: 1016/j.antiviral.2018.11.012.
  4. Jackson AC. Human rabies treatment: From palliation to promise. Viruses. 2024;16(1):160. doi: 3390/v16010160.
  5. Pardridge WM. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. BioDrugs. 2016;30(4):299–308. doi: 1007/s40259-016-0182-6.
  6. Johnsen KB, Bak M, Kempen PJ, Melander F, Burkhart A, Thomsen MS, et al. Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles. Theranostics. 2018;8(12):3416–3436. doi: 7150/thno.25228.
  7. Lafon M, Mégret F, Lafage M, Préhaud C. The innate immune facet of brain: Human neurons efficiently mobilize antiviral defences against rabies virus. J Virol. 2008;82(24):12311–12320. doi: 1128/JVI.01204-08.
  8. Jackson AC, Scott CA, Owen J, Weli SC, Rossiter JP. Therapy with minocycline aggravates experimental rabies in mice. J Virol. 2007;81(12):6248–6253. doi: 1128/JVI.00219-07.
  9. Jackson AC, Scott CA, Owen J, Weli SC, Rossiter JP. Therapy with minocycline aggravates experimental rabies in mice. J Virol. 2007;81(12):6248–6253. doi: 1128/JVI.00219-07.
  10. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–463. doi: 2183/pjab.93.027.
  11. Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis. J Infect Dis. 2016;213(8):1253–1261. doi: 1093/infdis/jiv586.
  12. Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis. Antiviral Res. 2019;172:104641. doi: 1016/j.antiviral.2019.104641.
  13. Kim J, Lee H, Park S, Choi Y, Kang M, Lee J, et al. A rabies virus nucleocapsid-like nanostructure vaccine based on dual-cationic lipid nanoparticles. ACS Nano. 2025.
  14. Kim JS, Lee HJ, Park SY, Choi Y, Kang M, Lee J, et al. Rabies virus-targeting nanoparticles for near-infrared phototheranostics. ACS Nano. 2025.
  15. Willoughby RE Jr, Tieves KS, Hoffman GM, Ghanayem NS, Amlie-Lefond CM, Schwabe MJ, et al. Survival after treatment of rabies with induction of coma. N Engl J Med. 2005;352(24):2508–2514. doi: 1056/NEJMoa050382.
  16. Jackson AC. Human rabies: A 2016 update. Curr Infect Dis Rep. 2016;18(11):38. doi: 1007/s11908-016-0540-y.
  17. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12(1–2):54–61. doi: 1016/j.drudis.2006.10.013.
  18. Lentz TL, Burrage TG, Smith AL, Crick J, Tignor GH. Is the acetylcholine receptor a rabies virus receptor? Science. 1982;215(4529):182–184. doi: 1126/science.7053569.
  19. Finke S, Conzelmann KK. Replication strategies of rabies virus. Virus Res. 2005;111(2):120–131. doi: 1016/j.virusres.2005.04.004.
  20. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25–35. doi: 1016/0378-5173(83)90064-9.
  21. Yousaf S, Ahmad M, Mahmood A, Ali M. Mathematical modeling approaches for nanoparticle-mediated drug delivery systems: Recent advances and future perspectives. J Control Release. 2020;325:706–724. doi: 1016/j.jconrel.2020.07.018.
Regular Issue Subscription Review Article
Volume 16
Issue 02
Received 29/06/2026
Accepted 07/07/2026
Published 05/08/2026
Publication Time 37 Days

Login

My IP

PlumX Metrics